From an enhanceosome to a repressosome: molecular antagonism between glucocorticoids and EGF leads to inhibition of wound healing
- PMID: 15644206
- DOI: 10.1016/j.jmb.2004.11.027
From an enhanceosome to a repressosome: molecular antagonism between glucocorticoids and EGF leads to inhibition of wound healing
Abstract
Wound healing in its complexity depends on the concerted activity of many signaling pathways. Here, we analyzed how the simultaneous presence of glucocorticoids (GC), retinoic acid (RA) and epidermal growth factor (EGF) affect wound healing at the molecular, cellular and tissue levels. We found that GC inhibit wound healing by inhibiting keratinocyte migration, whereas RA does not. Furthermore, GC block EGF-mediated migration, whereas RA does not. On the molecular level, these compounds target expression of one of the earliest markers of wound healing, cytoskeletal components, keratins K6 and K16. Both GC and RA repress their transcription, whereas EGF induces it. Interestingly, the GC inhibition is mediated by a repressosome complex consisting of four monomers of the GC receptor, beta-catenin and coactivator-associated-arginine-methyltransferase-1. GC are dominant, EGF cannot rescue GC-mediated inhibition. Pre-treatment of keratinocytes with GC shifts the balance towards the repressosome, allowing for dominant inhibition of K6 even in the presence of EGF or c-fos/c-jun. Although RA receptor gamma and glucocorticoid receptor bind to the same response element repressing transcription of keratins K6/K16, RA receptor interacts with the components of the EGF-enhanceosome (co-activators: glucocorticoid-receptor-interactive protein-1(GRIP-1)/steroid-receptors coactivator-1 (SRC-1)) without breaking it. Consequently, RA has a co-dominant effect with EGF: when present simultaneously, their effects balance each other. When keratinocytes are pre-treated with mitogen-activated protein kinase (MAPK) inhibitor, thus blocking EGF, the balance is shifted towards the RA repression. Similar to clinical findings, pre-treatment of keratinocytes with RA blocks GC-mediated inhibition. In summary, our results identify complex molecular mechanisms through which RA alleviates GC-mediated inhibition of wound healing.
Similar articles
-
Epidermal growth factor induces insulin receptor substrate-2 in breast cancer cells via c-Jun NH(2)-terminal kinase/activator protein-1 signaling to regulate cell migration.Cancer Res. 2006 May 15;66(10):5304-13. doi: 10.1158/0008-5472.CAN-05-2858. Cancer Res. 2006. PMID: 16707456
-
Regulation of keratinocyte shape, migration and wound epithelialization by IGF-1- and EGF-dependent signalling pathways.J Cell Sci. 2003 Aug 1;116(Pt 15):3227-38. doi: 10.1242/jcs.00610. J Cell Sci. 2003. PMID: 12829742
-
Epidermal growth factor (EGF)-mediated DNA-binding activity of AP-1 is attenuated in senescent human epidermal keratinocytes.Exp Dermatol. 2005 Jul;14(7):519-27. doi: 10.1111/j.0906-6705.2005.00317.x. Exp Dermatol. 2005. PMID: 15946240
-
Contributions of the epidermal growth factor receptor to keratinocyte motility.Microsc Res Tech. 1998 Dec 1;43(5):444-55. doi: 10.1002/(SICI)1097-0029(19981201)43:5<444::AID-JEMT10>3.0.CO;2-C. Microsc Res Tech. 1998. PMID: 9858341 Review.
-
[Epidermal growth factor (EGF) and wound healing].Duodecim. 1990;106(11):860-2. Duodecim. 1990. PMID: 1670323 Review. Finnish. No abstract available.
Cited by
-
Molecular pathogenesis of chronic wounds: the role of beta-catenin and c-myc in the inhibition of epithelialization and wound healing.Am J Pathol. 2005 Jul;167(1):59-69. doi: 10.1016/s0002-9440(10)62953-7. Am J Pathol. 2005. PMID: 15972952 Free PMC article.
-
Oral 11β-HSD1 inhibitor AZD4017 improves wound healing and skin integrity in adults with type 2 diabetes mellitus: a pilot randomized controlled trial.Eur J Endocrinol. 2022 Feb 28;186(4):441-455. doi: 10.1530/EJE-21-1197. Eur J Endocrinol. 2022. PMID: 35113805 Free PMC article. Clinical Trial.
-
Pharmacological and Genetic Inhibition of Caveolin-1 Promotes Epithelialization and Wound Closure.Mol Ther. 2019 Nov 6;27(11):1992-2004. doi: 10.1016/j.ymthe.2019.07.016. Epub 2019 Jul 30. Mol Ther. 2019. PMID: 31409528 Free PMC article.
-
Molecular markers in patients with chronic wounds to guide surgical debridement.Mol Med. 2007 Jan-Feb;13(1-2):30-9. doi: 10.2119/2006-00054.Brem. Mol Med. 2007. PMID: 17515955 Free PMC article.
-
Calreticulin: a multifunctional protein with potential therapeutic applications for chronic wounds.Front Med (Lausanne). 2023 Aug 24;10:1207538. doi: 10.3389/fmed.2023.1207538. eCollection 2023. Front Med (Lausanne). 2023. PMID: 37692787 Free PMC article. Review.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials
Miscellaneous